PBRM1 and neoplasm: To validate the role of POL&PBRM1 in immunotherapy further, we evaluated six transcriptional immunotherapy response signatures (T cell-inflamed gene expression profiles (T Cell GEP) signature,20 Tertiary lymphoid structures (TLS) signature,21 interferon-gamma (IFNG) signature,22 Tumor Inflammation Signature (TIS),23 Immunologic Constant of Rejection (ICR) signature24 and cytotoxic T lymphocytes (CTL) signature22) in TCGA.